Abstract
Asthma is a chronic disorder causing inflammation and reversible airway obstruction that affects approximately 300 million individuals worldwide. The incidence of asthma has nearly doubled in the past three decades resulting in higher rates of morbidity, mortality and health care costs. Despite the availability of several classes of asthma medications such as β-agonists, leukotriene modifiers and corticosteroids, up to 50% of asthmatics do not benefit from one or more of these drugs. Studies have shown that asthma and drug response phenotypes such as forced expiratory volume in one second (FEV1) are heritable traits, indicating a genetic component of variable response to asthma drugs. This review summarizes the findings of pharmacogenetic investigations on the three main classes of asthma medications. In addition, the limitations of these genetic studies are discussed and future research avenues are proposed to identify novel genetic factors. Although numerous genes have been associated with variable response to common asthma drugs, results are often contradictory across different studies, and remain to be confirmed in larger replication cohorts. Nevertheless, literature in asthma pharmacogenetics demonstrates that genetic variants influence response to asthma treatments and may be used for predictive testing prior to drug administration to avoid adverse reactions and increase drug efficacy.
Current Pharmaceutical Design
Title: Pharmacogenetics of Asthma Therapy
Volume: 15 Issue: 32
Author(s): Qing Ling Duan and Kelan G. Tantisira
Affiliation:
Abstract: Asthma is a chronic disorder causing inflammation and reversible airway obstruction that affects approximately 300 million individuals worldwide. The incidence of asthma has nearly doubled in the past three decades resulting in higher rates of morbidity, mortality and health care costs. Despite the availability of several classes of asthma medications such as β-agonists, leukotriene modifiers and corticosteroids, up to 50% of asthmatics do not benefit from one or more of these drugs. Studies have shown that asthma and drug response phenotypes such as forced expiratory volume in one second (FEV1) are heritable traits, indicating a genetic component of variable response to asthma drugs. This review summarizes the findings of pharmacogenetic investigations on the three main classes of asthma medications. In addition, the limitations of these genetic studies are discussed and future research avenues are proposed to identify novel genetic factors. Although numerous genes have been associated with variable response to common asthma drugs, results are often contradictory across different studies, and remain to be confirmed in larger replication cohorts. Nevertheless, literature in asthma pharmacogenetics demonstrates that genetic variants influence response to asthma treatments and may be used for predictive testing prior to drug administration to avoid adverse reactions and increase drug efficacy.
Export Options
About this article
Cite this article as:
Duan Ling Qing and Tantisira G. Kelan, Pharmacogenetics of Asthma Therapy, Current Pharmaceutical Design 2009; 15 (32) . https://dx.doi.org/10.2174/138161209789649510
DOI https://dx.doi.org/10.2174/138161209789649510 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ultrasound Assisted Faster and Milder Approach to 6H-pyrido[1,2-a] quinazolin-6-imine Derivatives as Potential Inhibitors of PDE4
Letters in Drug Design & Discovery Atopy and Role of Mast Cells in IgE-Mediated Allergic Diseases
Current Immunology Reviews (Discontinued) Type 2 Diabetes and Asthma: Systematic Review of the Bidirectional Relationship
Current Diabetes Reviews Editorial [Hot topic: Adenosine Receptor Ligands: Where Are We, and Where Are We Going? (Guest Editors: Tiziano Tuccinardi and Adriano Martinelli)]
Current Topics in Medicinal Chemistry Recent Advancement and Technological Aspects of Pulsatile Drug Delivery System - A Laconic Review
Current Drug Targets Editorial [ Targeting G Protein-Coupled 7TM Receptors in Inflammation Guest Editor: Dr. Trond Ulven ]
Current Topics in Medicinal Chemistry Preface
Current Drug Targets - Inflammation & Allergy Neuropharmacology of Vestibular System Disorders
Current Neuropharmacology YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer’s Disease
Current Neuropharmacology Preoperative Pulmonary Assessment: A Review
Current Respiratory Medicine Reviews Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Ganoderma lucidum (Ling-zhi): The Impact of Chemistry on Biological Activity in Cancer
Current Bioactive Compounds Study of SARS-nCoV2 Indian Isolates Gaining Insights into Mutation Frequencies, Protein Stability and Prospective Effect on Pathogenicity
Coronaviruses Aerosol Delivery in the Treatment of Lung Cancer
Current Cancer Drug Targets Targeting Pattern Recognition Receptors (PRRs) in Nano- Adjuvants: Current Perspectives
Current Bionanotechnology (Discontinued) Receptor Guided 3D-QSAR Analysis of Thieno[2,3-b]Pyridine-5- Carbonitrile Inhibitors of Protein Kinase C Theta (PKC-θ )
Combinatorial Chemistry & High Throughput Screening Gastroduodenal Disorders in Patients with CVID Undergoing Immunoglobulin Therapy
Current Pharmaceutical Biotechnology RNA-Mediated Therapeutics: From Gene Inactivation to Clinical Application
Current Topics in Medicinal Chemistry Structure, Function, Involvement in Diseases and Targeting of 14-3-3 Proteins: An Update
Current Medicinal Chemistry Biologics for ANCA-Associated Vasculitis
Inflammation & Allergy - Drug Targets (Discontinued)